Published in Eur J Obstet Gynecol Reprod Biol on April 01, 1983
Analysis of Candida albicans phenotypes from different geographical and anatomical sources. J Clin Microbiol (1983) 2.33
Prevalence of Candida dubliniensis isolates in a yeast stock collection. J Clin Microbiol (1998) 2.31
Candida albicans strain delineation. Clin Microbiol Rev (1990) 1.90
Management of genital candidiasis. Working Group of the British Society for Medical Mycology. BMJ (1995) 1.74
Biotyping of Candida albicans: results of an international collaborative survey. J Clin Microbiol (1989) 1.50
Use of modified resistogram to type Candida albicans isolated from cases of vaginitis and from faeces in the same geographical area. J Clin Pathol (1987) 0.79
A study of candidosis: the role of fomites. Genitourin Med (1991) 0.75
Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother (1990) 8.42
Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother (2003) 7.09
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
A simple system for the presumptive identification of Candida albicans and differentiation of strains within the species. Sabouraudia (1980) 5.47
Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev (2001) 4.49
Use of specialised isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients. Eur J Clin Microbiol Infect Dis (1997) 3.86
Molecular mechanisms of drug resistance in fungi. Trends Microbiol (1994) 3.55
NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans. EMBO J (2001) 3.48
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole. J Clin Microbiol (1996) 3.42
Genital yeasts in female patients attending a VD clinic. Br J Vener Dis (1975) 3.26
Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1992) 3.23
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (1999) 3.19
Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother (1980) 3.03
Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting. J Clin Microbiol (1992) 2.98
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis (1999) 2.96
Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol (2006) 2.86
Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. Br Med J (Clin Res Ed) (1985) 2.74
Modification and extension of tests for differentiation of Candida species and strains. Sabouraudia (1983) 2.68
Problems in the laboratory assessment of antifungal activity. Postgrad Med J (1979) 2.43
A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence. Infect Immun (1997) 2.35
Analysis of Candida albicans phenotypes from different geographical and anatomical sources. J Clin Microbiol (1983) 2.33
Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol (1994) 2.32
Application of DNA typing methods to Candida albicans epidemiology and correlations with phenotype. Rev Infect Dis (1990) 2.30
Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother (1982) 2.28
Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother (1997) 2.27
Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 2.27
Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect Immun (1997) 2.24
Virulence for mice of a proteinase-secreting strain of Candida albicans and a proteinase-deficient mutant. J Gen Microbiol (1983) 2.18
Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis. J Med Microbiol (1980) 2.17
Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J Clin Microbiol (2003) 2.17
An examination of the production of hydrolytic enzymes and toxins by pathogenic strains of Candida albicans. J Gen Microbiol (1971) 2.10
Genital candidosis. Clin Exp Dermatol (1982) 2.00
Candida infections in AIDS patients. Int J STD AIDS (1992) 1.98
The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother (1980) 1.75
New targets and delivery systems for antifungal therapy. Med Mycol (2000) 1.65
Morphogenesis in Candida albicans. Crit Rev Microbiol (1985) 1.65
Multilocus sequence typing of the pathogenic fungus Aspergillus fumigatus. J Clin Microbiol (2007) 1.65
Sequence of the Candida albicans gene encoding the secretory aspartate proteinase. J Med Vet Mycol (1991) 1.61
Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro. J Antimicrob Chemother (1984) 1.54
Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. J Med Vet Mycol (1986) 1.48
Relevance of antigenicity of Candida albicans growth phases to diagnosis of systemic candidiasis. Br Med J (1973) 1.47
Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol (1996) 1.45
Candida albicans proteinase as a virulence factor in the pathogenesis of Candida infections. Zentralbl Bakteriol Mikrobiol Hyg A (1985) 1.40
A set of constructed type spectra for the practical estimation of peptide secondary structure from circular dichroism. Anal Biochem (1997) 1.40
A morphology index for characterization of cell shape in Candida albicans. J Gen Microbiol (1989) 1.40
Tertiary syphilis. Sex Transm Infect (1999) 1.39
Prevalence of pathogenic yeasts and humoral antibodies to candida in diabetic patients. J Clin Pathol (1978) 1.38
Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. Proc Natl Acad Sci U S A (1998) 1.36
Biotyping of medically important fungi. Curr Top Med Mycol (1985) 1.35
Academic selection criteria and subsequent performance. Med Educ (1990) 1.30
Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J Antimicrob Chemother (1986) 1.29
The effect of growth medium of filament production in Candida albicans. Sabouraudia (1974) 1.27
Transfer of gonococcal pharyngitis by kissing? Br J Vener Dis (1974) 1.27
Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother (1984) 1.26
Enzyme activities associated with carbohydrate synthesis and breakdown in the yeast and mycelial forms of Candida albicans. J Gen Microbiol (1973) 1.26
Epidemiology of vaginal Candida infection: significance of numbers of vaginal yeasts and their biotypes. Eur J Obstet Gynecol Reprod Biol (1987) 1.25
Optimum conditions for initiation of filamentation in Candida albicans. Can J Microbiol (1975) 1.22
Meningococcal salpingitis. Br J Vener Dis (1976) 1.21
Control of an outbreak of systemic Candida albicans. Br Med J (Clin Res Ed) (1985) 1.19
Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J Gen Microbiol (1985) 1.16
Binding of plasma proteins to Candida species in vitro. J Gen Microbiol (1988) 1.14
Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. J Antimicrob Chemother (2001) 1.14
Identification of Candida glabrata by a 30-second trehalase test. J Clin Microbiol (2002) 1.11
Purified Candida albicans proteinase in the serological diagnosis of systemic candidosis. JAMA (1980) 1.09
Disseminated Candida infection syndrome in heroin addicts--dominance of a single Candida albicans biotype. J Med Microbiol (1987) 1.09
Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes. Antimicrob Agents Chemother (1997) 1.06
Detection of Candida precipitins. a comparison of double diffusion and counter immunoelectrophoresis. J Immunol Methods (1975) 1.02
Interactions of Candida albicans yeast cells, germ tubes and hyphae with human polymorphonuclear leucocytes in vitro. J Gen Microbiol (1984) 1.02
The variability of creatinine excretion in normal subjects, mental patients and pregnant women. Clin Chim Acta (1969) 1.01
Non-identity and authentication of two major reference strains of Candida albicans. J Med Vet Mycol (1991) 1.00
Correlation of susceptibility test results in vitro with response in vivo: ketoconazole therapy in a systemic candidiasis model. Chemotherapy (1985) 1.00
Expression of an epitope by surface glycoproteins of Candida albicans. Variability among species, strains and yeast cells of the genus Candida. J Med Vet Mycol (1990) 0.99
Cytomegalovirus in female patients attending a VD clinic. Br J Vener Dis (1975) 0.98
Distribution of pathogenic yeasts and humoral antibodies to candida among hospital inpatients. J Clin Pathol (1980) 0.97
Purification and properties of a glycoprotein acid phosphatase from Candida albicans. J Bacteriol (1973) 0.97
Systemic candidiasis in Spanish heroin addicts: a possible source of infection. J Infect Dis (1987) 0.96
Androgenic neurosteroids: anti-seizure effects in an animal model of epilepsy. Psychoneuroendocrinology (1998) 0.93
Adherence of Candida albicans to vaginal epithelia: significance of morphological form and effect of ketoconazole. Mykosen (1985) 0.93
Mechanism of action of D-serine dehydratase. Identification of a transient intermediate. Biochemistry (1979) 0.93
Colony variations in Candida species. Mycoses (1989) 0.92
Candida albicans GRX2, encoding a putative glutaredoxin, is required for virulence in a murine model. Genet Mol Res (2007) 0.91
Peptones and mycological reproducibility. Sabouraudia (1978) 0.91
Demonstration of a septal pore in budding Candida albicans yeast cells. Sabouraudia (1984) 0.91
Ecology and epidemiology of Candida species. Zentralbl Bakteriol Mikrobiol Hyg A (1984) 0.89
Chitinase levels in guinea pig blood are increased after systemic infection with Aspergillus fumigatus. Glycobiology (1996) 0.89
Ophthalmia neonatorum due to Branhamella (Neisseria) catarrhalis. Case reports. Br J Vener Dis (1981) 0.88
European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect (2011) 0.87
Circular-dichroism studies of the cytochrome b-c1 complex of Saccharomyces cerevisiae. Eur J Biochem (1978) 0.86
Cross-sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)-seropositive population: predisposing factors, epidemiology and antifungal susceptibility. Mycoses (1998) 0.86